Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Sinopharm Files for China Approval of COVID-19 Vaccine, Bloomberg Says
Sinopharm has filed for
In July,
Liu Jingzhen, Chairman of Sinopharm, told a
The unofficial reports about the filing did not specify which of the candidates would be reviewed. The two candidates were developed by different Sinopharm institutes,
Early-stage trials showed that the vaccines generated antibodies, an indicator of immunity, without serious side effects. However, the company will need to present data from large-scale Phase III trials to obtain regulatory approvals.
Sinopharm said it has the facilities to make 100 million doses of the COVID-19 vaccine this year and, by expanding its production capacity, it could produce 1 billion doses next year.
See our other articles on Sinopharm.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China